Mark Wegter

Bio

Mark Wegter, economist, joined LSP in 1998 and became a general partner in early 2001. He currently serves as Chairman of the supervisory board of Kiadis Pharma (NL/CDN) and as a supervisory board member for PamGene (NL), 4-Antibody (CH/G) and EyeSense (CH/G). He was also on the Supervisory Board of Jerini (G) until the company was listed on the Frankfurt stock exchange in November 2005 and on the Supervisory Board of OncoMethylome Sciences (B), until a year after the company was listed on The Euronext stock Exchange in June 2006. Mark has been involved in many of LSP’s investments, both early- and later-stage, including U-BiSys (NL) (which became Crucell after it merged with yet another of LSP’s portfolio companies), deVGen (B) (which was listed on the Euronext stock exchange in 2005), De Novo Pharmaceuticals (UK) and Kreatech Biotechnology (NL). Together with Joachim Rothe, Mark established LSP’s Munich office in late 2001 and has extended LSP’s foothold in Germany and Switzerland ever since. After returning to the Netherlands in 2007, he initiated and built LSP’s public investment franchise that focuses on investing in the public biotechnology capital markets. Mark started his career at ING Barings Investment Banking in Amsterdam and São Paulo, where he worked as a senior analyst on Global Risk Management and served as the assistant to a member of the executive committee, with worldwide responsibility for risk management. Mark has a Masters degree in business economics from the Erasmus University of Rotterdam.